Invicro Hires Edward Hogan as Senior Vice President of Clinical Operations

Invicro Hires Edward Hogan as Senior Vice President of Clinical Operations

BOSTON, MA, February 27, 2018 – Invicro, LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the hiring of Mr. Edward Hogan, M.S. as Senior Vice President of Clinical Operations.  Mr. Hogan brings extensive medical imaging and clinical research experience that will significantly advance Invicro’s clinical imaging core lab capabilities across all stages of the drug development pipeline (Phase I-IV).

“On behalf of the Invicro family, I welcome Ed to the team,” stated Dr. Jack Hoppin, Co-Founder and CEO of Invicro. “Ed’s appointment is a great addition to our clinical and senior leadership teams as he focuses on expanding our global clinical imaging capabilities into multiple therapeutic areas beyond neurology such as oncology, cardiovascular, and musculoskeletal to name a few. Through his leadership and his clinical operations expertise, our pharmaceutical and biotechnology sponsors will receive the most comprehensive imaging informatics service and support the industry has to offer.”

Mr. Hogan joins Invicro from PAREXEL, where he most recently initiated quality and process improvement efforts as the Vice President of the Quality First Program. Previously, he spent seven years as the Vice President of Imaging Operations, where he provided operational leadership, and launched core labs to support global growth in Europe, India, Japan and China.  During his time at PAREXEL he built and developed a cross-functional Medical Imaging team that grew from 20 to 450+ global employees to support over 1200 projects from Phase I-IV during his tenure.

“I am extremely excited to join the Invicro team,” Mr. Hogan stated. “I look forward to optimizing workflows that will leverage synergies between the core lab, the software team and the advanced analytics group.  Together, we will build upon our current best-in-class informatics offering that will provide research collaborators extensive analytics and secure data access.”

Prior to his sixteen-year career at PAREXEL, Mr. Hogan served as a Senior Medical Imaging Scientist at DuPont Merck where he led efforts to coordinate the imaging responsibilities of both internal and external core labs and earned the Executive Council Award for commitment to excellence. Mr. Hogan earned an MS in Electrical Engineering from Tufts and a BS in Electrical Engineering from the University of Lowell.

About Invicro

Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017.  Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant®® and iPACS®, has inspired a strong and growing presence in the market.  For more information, visit www.invicro.com

About Konica Minolta

Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/

Invicro becomes the latest industry partner to join Dementias Platform UK

Invicro becomes the seventh industry partner to join Dementias Platform UK, contributing expertise in brain imaging to further DPUK’s aim to accelerate treatments for dementia.

We are delighted to announce that Invicro, a leading provider of imaging services and software for research and drug development, is now an industry partner of Dementias Platform UK. Invicro joins the consortium of 16 other academic and industry partners who, together, are developing the infrastructure which supports and accelerates a new generation of clinical trials for dementia treatments.

State-of-the-art PET-MR scanner based at Invicro is part of DPUK’s Imaging network

Brain imaging expertise

Formerly known as Imanova, Invicro is uniquely placed to contribute to the work of DPUK, through their place as world experts in brain imaging. Being able to look in detail into the workings of the brain is a crucial element to scientists’ growing understanding of the complex mechanisms which lead to dementia. Scientists across the DPUK network are already benefitting from Invicro’s scientific and technical expertise in state-of-the-art brain imaging.

Invicro constitutes a key part of the DPUK imaging network and has helped to establish the new generation of PET-MR scanners that has been supported by DPUK investment. As one of the seven networked imaging sites, Invicro will be instrumental in multicentre studies, such as the MRC-funded Deep and Frequent Phenotyping study, due to get started early this year.

Invicro, in collaboration with DPUK, is also leading the MINDMAPS programme to establish novel biomarkers of mitochondrial dysfunction and synaptic loss for application to neurodegeneration.

“We are delighted to welcome Invicro as a formal partner of Dementias Platform UK. Invicro is a world leader in the provision of brain imaging services and we look forward to facilitating a new generation of much larger, deeper studies into dementia” John Gallacher, Director, DPUK.

Why Invicro decided to join DPUK

Invicro is committed to applying imaging to disease understanding and drug development in a range of neurodegenerative diseases. DPUK provides a rich network of disease experts, imaging researchers and commercial organisations who share in the common goal of finding therapies for dementia. DPUK is an important initiative that brings together the best of academia and industry to target dementia and we are excited to be part of it.” Prof Roger Gunn, Executive Vice President – Quantitative Data Sciences, Invicro.

As partners, representatives of Invicro now sit on the Company Partner Forum – a group which advises the work of the platform to ensure it is meeting the needs of industry and making the most of what they have to offer.

Invicro joins a consortium of industry and academic partners at DPUK. By bringing the worlds of university and industry research together in a radical and novel way, DPUK is able to promote cross-fertilisation of ideas, streamline the process from ideas to new treatments, and help researchers to work together on the challenges and opportunities in dementia research.

About Invicro

Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017.  Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant®® and iPACS®, has inspired a strong and growing presence in the market.  For more information, visit www.invicro.com

About DPUK

Dementias Platform UK is a public-private partnership funded by the Medical Research Council. DPUK’s partners – ten universities and seven pharmaceutical companies – have joined forces with the aim of accelerating research towards effective treatment for dementia by improving access to data.

By bringing together records from over 40 different cohort studies – including brain scans, genetics and clinical records – DPUK is creating the world’s richest source of people data for use in research and drug development for dementia. This free-to-access resource of cohort data is available for use by any bona fide researcher who is interested in investigating dementia, whether based within a university or industry context.

DPUK facilitates safe and secure access to this data through its Data Portal, enabling research and analyses at a scale that has not previously been possible for studies into dementia.

DPUK wishes to promote scientific research using cohort study data. It has an active programme of experimental medicine and funds research using cohort data.

www.dementiasplatfom.uk

Invicro Appoints George Abe as Senior Vice President, Pathology

BOSTON, MA, February 20, 2018 – Invicro LLC, a Konica Minolta company and a leading provider of imaging services and software for research and drug development, today announced the hiring of Mr. George Abe, as Senior Vice President of Pathology.

(more…)

Ambry Genetics and Invicro Announce Partnership to Provide Enhanced Capabilities with Advanced Genomics Services to Enable Precision Medicine

Ambry Genetics and Invicro Announce Partnership to Provide Enhanced Capabilities with Advanced Genomics Services to Enable Precision Medicine

Partnership provides Pharmaceutical Companies a more Comprehensive Solution in an Effort to Improve Patient Care

(Aliso Viejo, CA) January 30, 2018: Ambry Genetics Corporation (Ambry), leaders in genetic testing, announced today they will partner with Invicro, a leading provider of imaging services and software for research and drug development, to provide customized genomics and imaging services for the pharmaceutical and biotechnology industry, with a specialized focus on oncology and neurodegenerative diseases.

Both Invicro and Ambry Genetics were acquired by Konica Minolta in 2017 as a part of Konica Minolta’s expansion into the clinical healthcare space, with a special emphasis on precision medicine. Konica Minolta’s mission is to improve patient care, from disease diagnosis to drug discovery to companion diagnostic development. This unique partnership combines advanced technologies to deliver a more efficient solution, in an effort to expedite new drug discovery and development. Both companies will operate as independent subsidiaries.

“We are excited to join the Konica Minolta precision medicine family and to have this opportunity to integrate our research services and informatics platform with the tier-one genomics offerings at Ambry,” said Dr. Jack Hoppin, Co-Founder and CEO of Invicro. “Together, we now offer our collaborators a novel panel of quantitative biomarker assays from gene-to-protein-to-cell-to-organ from discovery research through multi-center clinical trials.”

“Invicro’s imaging platform is an ideal complement to Ambry’s advanced genomics services for a comprehensive solution designed to improve the productivity of the biopharmaceutical industry,” said Dr. Phillip Gray, VP of Advanced Genomic Services at Ambry. “Additionally, with Invicro’s experience and extensive biopharmaceutical network, we believe our combined expertise will deliver industry-leading solutions towards the fulfillment of precision medicine.”

 

About Ambry

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry is an established leader in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information, visit http://www.ambrygen.com/

About Invicro

Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017.  Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant®® and iPACS®, has inspired a strong and growing presence in the market.  For more information, visit www.invicro.com

 

PR Contact: Aaron Schmidt, Sr. Manager, Communications

Phone: 949.457.4679
Email: aschmidt@ambrygen.com

 

Boston-Based Invicro Further Expands Imaging Capabilities with Acquisition of Core Clinical, Inc.

Boston-Based Invicro Further Expands Imaging Capabilities with Acquisition of Core Clinical, Inc.

 

BOSTON, MA, October 26, 2017 – Invicro, LLC, a leading provider of imaging services and software for research and drug development, announced today that it has completed the acquisition of Core Clinical, Inc., a medical imaging core lab based in Bucks County, PA.

(more…)

Konica Minolta Accelerates Expansion of Precision Medicine Business Through Acquisition of US-based Pharmaceutical Research Company, Invicro

Konica Minolta Accelerates Expansion of Precision Medicine Business Through Acquisition of US-based Pharmaceutical Research Company, Invicro

Through molecular digital imaging technology, acquisition offers new value for drug discovery and development focused on the fields of immuno-oncology and neurodegenerative disease

 TOKYO & BOSTON–(BUSINESS WIRE)–Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902; ISIN: JP3300600008) and Boston-based Invicro LLC (“Invicro”) today announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.

(more…)

Invicro acquires Imanova to expand global imaging capabilities

Combined business delivers world-leading imaging capabilities to drive
improved decision-making from early drug discovery to late-phase clinical development

BOSTON, MA, September 12, 2017 – Invicro, LLC, a leading provider of imaging services and software for research and drug development, announced today the acquisition of UK-based Imanova. Invicro and Imanova will merge all activities to establish the world’s largest provider of translational imaging services and analytics from pre-clinical development through to late-phase clinical trials.

(more…)

Bioverativ and Invicro Form Novel, Advanced Imaging Collaboration Focused on Improving Management of Joint Health in People with Hemophilia

Builds on companies’ first-of-its-kind initiative using radiolabeled imaging to understand the impact of the extravascular distribution of factor IX on joint health

Strategic collaboration will seek to advance the adoption of ultrasound imaging in the diagnosis and management of joint disease in people with hemophilia

WALTHAM, Mass. & BOSTON, Mass – August 24, 2017 – Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, and Invicro, LLC, a leading provider of imaging services and analysis for pharmaceutical research and development, today announced that they have formed a strategic collaboration focused on expanding the use and adoption of leading imaging technologies, including ultrasound and radiolabeled imaging, to improve the diagnosis and management of joint disease in people with hemophilia.

(more…)

MIND MAPS – scanning completed on the first participants

Invicro UK (formerly Imanova) is pleased to announce that the scanning has been completed on the first participants in the MIND MAPS programme. MIND MAPS is a multi-arm pre-competitive programme led by Invicro UK and drawing together both academic and commercial partners with the aim of characterizing imaging markers of progressive neurodegeneration.

MIND MAPS will seek to quantify molecular targets associated with mitochondrial and synaptic dysfunction using three PET ligands ( [11C]UCB-J, [11C]SA4503 and [18F]BCPP-EF targeting the SV2A glycoprotein, the sigma 1 receptor and the mitochondrial complex 1, respectively).

Ilan Rabiner, Invicro UK’s CMO, said “MIND MAPS represents an important pre-competitive initiative to deliver the first robust molecular characterization of the progression of neurodegeneration. Our hope is to deliver improved disease understanding with a view to facilitate the development of disease modifying drugs targeting these disorders”.

This program will compare the density of these molecular targets in the healthy human brain across a wide range of ages (20-85 years) and in patients with a variety of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and fronto-temporal dementia).

MIND MAPS will complete the first phase by the end of 2018 with the aim of validating imaging biomarkers for use in future Phase II proof-of-concept studies.

 

Imanova Secures License from Cerveau Technologies, Inc. to Manufacture Investigational Tau Ligand, [18F]MK-6240

Invicro UK (formerly Imanova) has signed an agreement that grants the company the right to manufacture for distribution and on-site use [18F]MK-6240, an early stage investigational Positron Emission Tomography (PET) imaging agent. This will facilitate studies assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s Disease.

(more…)